Welcome to our dedicated page for Sana Biotechnology SEC filings (Ticker: SANA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sana Biotechnology, Inc. (NASDAQ: SANA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sana’s common stock is registered on The Nasdaq Global Select Market under the symbol SANA, and its filings offer detailed information on financial performance, capital markets activity, and progress in its engineered cell programs.
Investors can review current reports on Form 8-K in which Sana furnishes quarterly financial results, discusses non-GAAP measures, and describes material events such as equity offerings, impairment charges related to facilities, and portfolio prioritization decisions. These filings also summarize clinical and preclinical updates for programs like UP421, SC451, and in vivo CAR T candidates built on the fusogen platform, as well as interactions with regulators and key scientific publications.
Other SEC documents, including registration statements and prospectus supplements referenced in Sana’s 8-K filings, outline the terms of public offerings of common stock and pre-funded warrants, at-the-market sales programs, and related underwriting agreements. Governance-related 8-K items describe changes in board composition and senior leadership roles, with explanations of director resignations and executive transitions.
On Stock Titan, Sana’s filings are paired with AI-powered summaries that help explain the significance of each document, from quarterly results to material agreements. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while specialized views make it easier to identify items related to financing transactions, clinical disclosures, and corporate governance. This structure allows users to navigate Sana’s regulatory history and better understand how its engineered cell and gene therapy initiatives are reflected in official SEC reports.
Sana Biotechnology EVP and CFO Brian Piper filed an initial Form 3 insider report. This filing establishes his status as a reporting insider of Sana Biotechnology, Inc. It does not list any buy or sell transactions and serves as a baseline disclosure of his beneficial ownership reporting obligations.
Sana Biotechnology appointed Brian Piper as Executive Vice President, Chief Financial Officer, Treasurer, and Principal Financial Officer effective February 17, 2026, replacing CEO Steve Harr in the acting principal financial officer role. Piper brings over 25 years of biopharmaceutical finance experience, including CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude Therapeutics, and Aevi Genomic Medicine, plus senior finance roles at Shire.
Under his offer letter, Piper will receive a $515,000 annual base salary, a target bonus equal to 40% of base salary, an option to purchase 900,000 shares with a four-year vesting schedule, and 200,000 RSUs vesting over four years, all subject to continued service. If terminated without cause or he resigns for good reason outside a change-in-control window, he is eligible for nine months of salary continuation and up to nine months of COBRA coverage, subject to a release of claims. He also participates in Sana’s Change in Control Severance Plan.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Sana Biotechnology Inc. common stock. BlackRock reports beneficial ownership of 13,643,304 shares, representing 5.1% of Sana’s outstanding common stock as of the event date.
BlackRock has sole voting power over 13,405,747 shares and sole dispositive power over 13,643,304 shares, with no shared voting or dispositive power. The filing explains that these shares are held across certain BlackRock business units in the ordinary course of business, and that the position is not intended to change or influence control of Sana.
The disclosure notes that various underlying persons have rights to receive dividends or sale proceeds from the shares, but that no single such person has an interest in more than 5% of Sana’s total outstanding common stock.
Sana Biotechnology, Inc. furnished an updated corporate presentation tied to its appearance at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress across its cell therapy platforms, including UP421, a primary pancreatic islet cell therapy using its hypoimmune platform, which at 12 months post-transplant in a type 1 diabetes patient without immunosuppression continued to survive, evade immune detection, and function.
The company also stated it remains on track to file an investigational new drug application and begin a Phase 1 trial for SC451, a hypoimmune-modified, iPSC-derived pancreatic islet cell therapy, as early as this year, and announced a goal of generating initial human data for SG293, an in vivo CD19-directed CAR T cell therapy, as early as this year. The information is furnished under Regulation FD and is not deemed filed or incorporated into other SEC reports unless specifically referenced.
Sana Biotechnology director Hans Edgar Bishop reported an equity award. On January 5, 2026, he acquired 6,157 shares of Common Stock in a transaction coded "A" for acquisition. The footnote explains these consist of fully vested restricted stock units, with a reported price of $0.00 per share, indicating no cash purchase. After this grant, Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology common stock in direct ownership.
Sana Biotechnology, Inc. officer Susan D. Wyrick, identified as Acting Chief Financial Officer and Principal Accounting Officer, reported equity transactions involving company stock. On January 2, 2026, 7,500 restricted stock units were converted to common stock at $0.00 per share, reflecting previously granted compensation that vested 40% on January 2, 2025 and 60% on January 2, 2026. The corresponding RSU award balance went to zero after this conversion.
On January 5, 2026, Wyrick reported a transaction coded "F" involving 2,407 shares of common stock at $4.27 per share, after which she directly held 185,883 shares of Sana Biotechnology common stock.
Sana Biotechnology, Inc. officer Susan D. Wyrick reported activity in company stock. On December 13, 2025, 3,400 restricted stock units vested and converted into common stock at a price of $0.00 per share, increasing her directly held shares. On December 15, 2025, she disposed of 873 shares at $5.22 per share, after which she held 180,790 shares of common stock directly. The filing notes that the restricted stock unit award vested in full on December 13, 2025 and identifies Wyrick as Acting Chief Financial Officer and Principal Accounting Officer.
Sana Biotechnology reported Q3 2025 results, highlighting lower operating expenses and a narrower loss. Total operating expenses were $43.5 million, down from $61.8 million a year ago, driven by research and development of $30.1 million and general and administrative of $10.3 million. Net loss was $42.2 million (basic and diluted net loss per share $0.16), improving from $59.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $153.1 million as of September 30, 2025. The company completed an August underwritten offering for net proceeds of approximately $80.6 million and sold 7.3 million shares under an ATM for $28.6 million in Q3. Management states existing liquidity, together with these proceeds, will fund planned operations for at least one year from the filing. For the first nine months, operating cash outflow was $111.2 million; results include a non-cash impairment of $44.6 million recognized in Q2 tied to facilities in Bothell and Seattle. Stockholders’ equity was $195.3 million. Shares outstanding were 266,366,120 as of October 29, 2025.
Sana Biotechnology furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information was furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated by reference.
Insider acquisition recorded for Sana Biotechnology (SANA). A Form 4 filed for director Hans Edgar Bishop shows an acquisition on 10/06/2025 of 5,628 shares via fully vested restricted stock units (RSUs) issued at $0.00 as part of compensation. Following the transaction, the reporting person beneficially owns 5,834,583 shares in total. The filing was signed by an attorney-in-fact on 10/07/2025. The entry is coded as a non-derivative acquisition and the explanation confirms these were fully vested RSUs.